Teva Licenses Cephalon PARP Inhibitor To Checkpoint Therapeutics

Teva Pharmaceutical Industries Ltd. has licensed an oral PARP inhibitor originally developed by Cephalon to Fortress Biotech company, Checkpoint Therapeutics, Inc. one of several subsidiary companies of Fortress Biotech, Inc. Checkpoint will obtain exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, oral PARP (poly ADP-ribose polymerase) inhibitor, CEP-9722, which is in early clinical development for solid tumors.

Teva Pharmaceutical Industries Ltd. has licensed an oral PARP inhibitor originally developed by Cephalon to Fortress Biotech company, Checkpoint Therapeutics, Inc. one of several subsidiary companies of Fortress Biotech, Inc. Checkpoint will obtain exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, oral PARP (poly ADP-ribose polymerase) inhibitor, CEP-9722, which is in early clinical development for solid tumors.

The small molecule selective inhibitor of PARP-1 and PARP-2 enzymes, CEP-9722, will be developed by Checkpoint as a monotherapy and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category